All In Biotech

NDA 215842 · Novo

Rivfloza

Nedosiran Sodium · Injection

NovelBreakthrough therapyOrphan

CDER novel approval, Sep 29, 2023: To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function

Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Sep 29, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5

1 Phase 3, 1 recruiting

FAERS reports

12

8 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 3, 2025.

RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 [see Clinical Pharmacology (‎ 12.3 )], Clinical Studies (‎ 14.1 )]. RIVFLOZA is an LDHA -directed small interfering RNA indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 . (‎ 1 )

Mechanism: Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc-conjugated sugars bind to asialoglycoprotein receptors (ASGPR) to deliver nedosiran to hepatocytes. Nedosiran reduces levels of hepatic lactate dehydrogenase (LDH) via the degradation of LDHA messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. The reduction of hepatic LDH by nedosiran reduces the production of oxalate by the liver, thereby reducing subsequent oxalate burden.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 27, 2025 Supplement 2 · Efficacy OrphanLabelLetter
  • Sep 29, 2023 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
3 products under this application
  • RIVFLOZA · NEDOSIRAN SODIUM EQ 160MG BASE/ML (EQ 160MG BASE/ML) · SOLUTION, INJECTION · Prescription
  • RIVFLOZA · NEDOSIRAN SODIUM EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML) · SOLUTION, INJECTION · Prescription
  • RIVFLOZA · NEDOSIRAN SODIUM EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML) · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nedosiran" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • urine oxalate increased3
  • inappropriate schedule of product administration2
  • rash2
  • abdominal pain1
  • amenorrhoea1
  • bone pain1
  • death1
  • dehydration1
  • diabetes mellitus1
  • drug ineffective1
  • febrile infection1
  • haemoglobin increased1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20243
20259

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Novo

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.